Showing results (951-960 of 5,983) with videos related to

Sort By:
Pageof 599
Molecular Cancer Therapeutics|August 13, 2009
A heterotypic bystander effect for tumor cell killing after adeno-associated virus/phage-mediated, vascular-targeted suicide gene transferMartin Trepel, Charlotte A Stoneham, Hariklia Eleftherohorinou, et al.
Molecular Cancer Therapeutics|August 13, 2009
Oncolytic adenoviruses targeted to cancer stem cellsJoshua J Short, David T Curiel
Molecular Cancer Therapeutics|August 13, 2009
HYD1-induced increase in reactive oxygen species leads to autophagy and necrotic cell death in multiple myeloma cellsRajesh R Nair, Michael F Emmons, Anne E Cress, et al.
Molecular Cancer Therapeutics|October 8, 2009
In vivo effects of targeting CD79b with antibodies and antibody-drug conjugatesBing Zheng, Reina N Fuji, Kristi Elkins, et al.
Molecular Cancer Therapeutics|October 8, 2009
BH3-only proteins Mcl-1 and Bim as well as endonuclease G are targeted in spongistatin 1-induced apoptosis in breast cancer cellsUta M Schneiders, Lilianna Schyschka, Anita Rudy, et al.
Molecular Cancer Therapeutics|May 6, 2010
ENMD-1198, a new analogue of 2-methoxyestradiol, displays both antiangiogenic and vascular-disrupting propertiesEddy Pasquier, Snega Sinnappan, Marcia A Munoz, et al.
Molecular Cancer Therapeutics|July 29, 2010
Heat shock protein 90 inhibition depletes TrkA levels and signaling in human acute leukemia cellsRekha Rao, Srilatha Nalluri, Warren Fiskus, et al.
Molecular Cancer Therapeutics|July 29, 2010
Immune competency of a hairless mouse strain for improved preclinical studies in genetically engineered miceBeverly S Schaffer, Marcia H Grayson, Joy M Wortham, et al.
Molecular Cancer Therapeutics|August 21, 2010
Phase I study of the selective Aurora A kinase inhibitor MLN8054 in patients with advanced solid tumors: safety, pharmacokinetics, and pharmacodynamicsTeresa Macarulla, Andres Cervantes, Elena Elez, et al.
Molecular Cancer Therapeutics|April 22, 2010
X-linked inhibitor of apoptosis protein inhibits apoptosis in inflammatory breast cancer cells with acquired resistance to an ErbB1/2 tyrosine kinase inhibitorKatherine M Aird, Rami B Ghanayem, Sharon Peplinski, et al.
Pageof 599